Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Perindopril (Coversyl) prevents cardiovascular death and MI in coronary disease patients regardless of their cardiovascular risk.

Opie L, Dalby T, Naidoo DP.

Cardiovasc J S Afr. 2003 Sep-Oct;14(5):277-9. No abstract available.

2.

[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].

Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C.

Ital Heart J. 2005 Nov;6 Suppl 7:24S-32S. Review. Italian.

PMID:
16485514
3.
4.

Perindopril protects diabetics with coronary disease from cardiovascular death and heart attacks.

[No authors listed]

Cardiovasc J S Afr. 2004 Mar-Apr;15(2):98. No abstract available.

5.

[The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].

Ferrari R, Ambrosio G, Chiariello M.

Ital Heart J. 2005 Nov;6 Suppl 7:3S-4S. Italian. No abstract available.

PMID:
16485511
6.

EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?

Sica DA.

J Clin Hypertens (Greenwich). 2004 Feb;6(2):91-5. Review.

7.

ACE inhibitors: the impact of the EUROPA study on CAD.

[No authors listed]

Cardiovasc J S Afr. 2003 Jul-Aug;14(4):211-2. No abstract available.

8.

Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.

Brugts JJ, Ferrari R, Simoons ML.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):345-60. doi: 10.1586/erc.09.2. Review. Erratum in: Expert Rev Cardiovasc Ther. 2009 Jun;7(6):722.

PMID:
19379059
9.

[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].

Rapezzi C, Ciliberti P, Graziosi M, Riva L.

Ital Heart J. 2005 Nov;6 Suppl 7:40S-47S. Review. Italian.

PMID:
16485516
10.

Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.

Ferrari R, Bertrand ME, Remme WJ, Simoons ML, Deckers JW, Fox KM.

Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1037-46. Review.

PMID:
18035919
11.

[Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].

Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.

Ital Heart J. 2005 Nov;6 Suppl 7:14S-23S. Review. Italian.

PMID:
16485513
12.

Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.

Ferrari R.

Curr Med Res Opin. 2008 Dec;24(12):3543-57. doi: 10.1185/03007990802576302 . Review.

PMID:
19032136
13.

The effect of early perindopril administration on mortality and morbidity in patients with high risk of acute myocardial infarction.

Protopopescu T, Toporan D, Paraschiv A, Ioan A.

Rom J Intern Med. 1998 Jul-Dec;36(3-4):197-205.

PMID:
10822516
14.

Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?

White HD.

Lancet. 2003 Sep 6;362(9386):755-7. No abstract available.

PMID:
13678865
15.

Improving endothelial function and reducing remodeling post-MI are key to perindopril benefits in coronary artery disease.

[No authors listed]

Cardiovasc J S Afr. 2006 Jul-Aug;17(4):203-4. No abstract available.

16.

New pathophysiological insights explain life-saving benefits of perindopril in coronary artery disease patients.

[No authors listed]

Cardiovasc J S Afr. 2004 Sep-Oct;15(5):248-9. No abstract available.

17.

Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.

Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML; EUROPA investigators.

Int J Cardiol. 2007 Sep 14;121(1):57-61. Epub 2007 Jan 31.

PMID:
17270296
18.

The EUROPA trial.

Brophy JM.

Lancet. 2003 Dec 6;362(9399):1936; author reply 1936-7. No abstract available.

PMID:
14667759
19.

Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.

Bertrand ME, Fox KM, Remme WJ, Ferrari R, Simoons ML.

Arch Cardiovasc Dis. 2009 Feb;102(2):89-96. doi: 10.1016/j.acvd.2008.10.012. Epub 2009 Jan 19.

20.

[The effect of Coversyl].

Jacobsen K.

Ugeskr Laeger. 2002 Aug 5;164(32):3791; author reply 3791-2. Danish. No abstract available.

PMID:
12362619

Supplemental Content

Support Center